Premium
Present Status of Modified Hemoglobin as Blood Substitutes and Oral Therapy for End Stage Renal Failure Using Artificial Cells Containing Genetically Engineered Cells
Author(s) -
CHANG THOMAS MING SWI
Publication year - 2001
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2001.tb03848.x
Subject(s) - genetically engineered , genetically modified organism , medicine , blood substitute , hemoglobin , pharmacology , biology , biochemistry , gene
A bstract : Artificial cell or bioencapsulation has been developed for use in bioartificial organs, drug delivery, blood substitutes, and other areas. Recent rapid advances in modified hemoglobin blood substitutes have resulted in advance stages of Phase III clinical trials. Another area of use is in oral therapy, using artificial cells microencapsulated with genetically engineered cells for use in end stage renal failure and other conditions.